CDH17 and neuroendocrine neoplasm: Feng et al. demonstrated that anti-CDH17 CAR T-cells not only eradicate CDH17-expressing neuroendocrine tumors (NETs), gastric, pancreatic, and colorectal cancers in xenograft or autochthonous mouse models, but also do not attack normal intestinal epithelial cells, which also express CDH17 to cause toxicity [148].